Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation

Title:Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation

Volume: 18 Issue: 19

Author(s): Aswini Krishnan, James Wilson and Hing Y. Leung

Affiliation:

Keywords: Microtubule (MT), microtubule associated proteins (MAPs), microtubule targeting agents (MTAs), chemotherapy, tubulin heterodimers, polymerases, angiogenesis, neutropenia, p21-activated kinase 6 (PAK6), prostate cancer

Abstract: The microtubule (MT) represents a highly validated target for therapy. Insights into the complex nature of the dynamic microtubule physiology will provide the basis for developing novel microtubule targeting agents with enhanced efficacy and minimised toxicity. In this article, with an emphasis on translational applications, we have summarised relevant aspects of tubulin physiology in the context of developing MT binding agents as therapeutic agents. Case studies were included to illustrate therapeutic developments in prostate cancer and current strategies to discover novel agents or targets for therapy.

Cite this article as:

Krishnan Aswini, Wilson James and Y. Leung Hing, Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626111